Early results from a 3rd gen EGFR-TKI in advanced NSCLC from bbb sign in Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Dr Cho speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase I/II trial of lazertinib, a highly selective and irreversible investigational 3rd-generation EGFR-TKI.nnHe describes the activity of lazertinib in targeting EGFR mutations and T790M mutation, while sparing wild type, and that the drug penetrates the blood-brain barrier (BBB) which has led to marked response in brain metastases.nnAcross all evaluable patients, the overall response rate
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)